Koninklijke Philips N.V. (PHG)
NYSE:PHG
Want to see PHG full AI Analyst Report?
PHG Stock Chart & Stats
$29.80
$0.02(0.06%)
At close: 4:00 PM EST
$29.80
$0.02(0.06%)
Day’s Range― - ―
52-Week Range$21.95 - $33.44
Previous CloseN/A
Volume160.28K
Average Volume (3M)954.79K
Market Cap
$24.96B
Enterprise Value$26.14B
Total Cash (Recent Filing)$2.79B
Total Debt (Recent Filing)$8.09B
Price to Earnings (P/E)24.8
Beta0.91
Next Earnings
May 06, 2026EPS Estimate
0.23Next Dividend Ex-DateN/A
Dividend Yield3.3%
Share Statistics
EPS (TTM)0.71
Shares Outstanding962,920,100
10 Day Avg. Volume935,116
30 Day Avg. Volume954,790
Financial Highlights & Ratios
PEG Ratio-0.11
Price to Book (P/B)2.02
Price to Sales (P/S)1.24
P/FCF Ratio24.84
Enterprise Value/Market Cap1.05
Enterprise Value/Revenue1.47
Enterprise Value/Gross Profit3.24
Enterprise Value/Ebitda9.93
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.78
Revenue Forecast (FY)$20.83B
Bulls Say, Bears Say
Bulls Say
Innovation Pipeline & Strategic M&AA sustained innovation pipeline and targeted M&A expand clinical offerings and addressable markets. New platforms (helium-free MRI, spectral CT, AI navigation) and SpectraWAVE broaden intervention and imaging portfolios, improving product differentiation, attach rates and long‑term gross‑margin potential.
Recurring Revenue Via Large PartnershipsStrong order momentum and enterprise partnerships deepen installed base and recurring service/software revenue. Large multi‑year deals for monitoring and imaging IT increase revenue visibility, raise attach rates for services and consumables, and underpin durable cash flows over multiple years.
Productivity-driven Margin RecoveryMaterial productivity gains have demonstrably improved margins and cash generation. Continued €1.5bn program plus prior €2.5bn savings create structural cost flexibility, supporting management targets, insulating margins from some headwinds and enabling reinvestment in R&D and service capabilities.
Bears Say
Respironics Legal & Regulatory OverhangExtended legal and regulatory obligations from the Respironics recall are a multi‑year structural risk. Continued investigations, consent‑decree actions and settlement payouts increase compliance costs, create uncertain future cash outflows, and weigh on reputation and capital allocation flexibility.
Tariff And Trade-related Margin PressureSustained tariff exposure materially compresses operating margins unless fully mitigated. Even with pricing, localization and productivity, a recurring €250–300m headwind forces structural cost adjustments, can reduce investment in innovation or services, and raises execution risk across global supply chains.
Multi‑year Earnings And Cash VolatilityHistorically volatile earnings and uneven cash conversion reduce predictability of organic funding and dividends. Recoveries in 2025 are meaningful but not yet proven durable; ongoing sensitivity to one‑offs and working‑capital swings raises refinancing, investment and margin sustainability risks over the medium term.
Koninklijke Philips News
PHG FAQ
What was Koninklijke Philips N.V.’s price range in the past 12 months?
Koninklijke Philips N.V. lowest stock price was $21.95 and its highest was $33.44 in the past 12 months.
What is Koninklijke Philips N.V.’s market cap?
Koninklijke Philips N.V.’s market cap is $24.96B.
When is Koninklijke Philips N.V.’s upcoming earnings report date?
Koninklijke Philips N.V.’s upcoming earnings report date is May 06, 2026 which is in 3 days.
How were Koninklijke Philips N.V.’s earnings last quarter?
Koninklijke Philips N.V. released its earnings results on Feb 10, 2026. The company reported $0.715 earnings per share for the quarter, beating the consensus estimate of $0.565 by $0.15.
Is Koninklijke Philips N.V. overvalued?
According to Wall Street analysts Koninklijke Philips N.V.’s price is currently Overvalued.
Does Koninklijke Philips N.V. pay dividends?
Koninklijke Philips N.V. pays a Annually dividend of $0.886 which represents an annual dividend yield of 3.3%. See more information on Koninklijke Philips N.V. dividends here
What is Koninklijke Philips N.V.’s EPS estimate?
Koninklijke Philips N.V.’s EPS estimate is 0.23.
How many shares outstanding does Koninklijke Philips N.V. have?
Koninklijke Philips N.V. has 962,920,100 shares outstanding.
What happened to Koninklijke Philips N.V.’s price movement after its last earnings report?
Koninklijke Philips N.V. reported an EPS of $0.715 in its last earnings report, beating expectations of $0.565. Following the earnings report the stock price went up 11.107%.
Which hedge fund is a major shareholder of Koninklijke Philips N.V.?
Currently, no hedge funds are holding shares in PHG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Koninklijke Philips Stock Smart Score
Company Description
Koninklijke Philips N.V.
Koninklijke Philips N.V. operates as a health technology company in North America and internationally. It operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. The company provides diagnostic imaging solutions, includes magnetic resonance imaging, computed tomography (CT) systems, X-ray systems, and detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; integrated interventional systems; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; proprietary software to enable diagnostics and intervention; and enterprise diagnostic informatics products and services. It also offers acute patient management solutions; emergency care solutions; sleep and respiratory care solutions; and electronic medical record and care management solutions. In addition, the company provides power toothbrushes, brush heads, and interdental cleaning and teeth whitening products; infant feeding and digital parental solutions; and male grooming and beauty products and solutions. It has a strategic collaboration with Ibex Medical Analytics Ltd. to jointly promote the digital pathology and AI solutions to hospitals, health networks, and pathology laboratories worldwide, as well as a strategic partnership agreement with NICO.LAB. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.
PHG Company Deck
PHG Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveys a broadly positive operational and financial performance: strong Q4 order intake and sales acceleration, substantial margin expansion, robust Personal Health and Connected Care momentum, significant productivity delivered and an active innovation pipeline. These positives are balanced by tangible near‑term headwinds — notably tariffs (annualized impact in 2026), ongoing Respironics‑related legal and regulatory matters, China tender dynamics, and some D&T margin pressure and Q1 phasing risk. Management has mitigations in place (productivity programs, pricing, localization) and a clear guide for 2026 (3%–4.5% sales growth; 12.5%–13% EBITDA margin), which supports confidence in execution despite the known risks.View all PHG earnings summariesTechnical Analysis
Ownership Overview
―
Insiders
0.49% Mutual Funds
0.95% Other Institutional Investors
98.30% Public Companies and
Individual Investors